Poop pills or procedure? fecal transplants tested for immunotherapy side effect

NCT ID NCT04883762

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether fecal microbiota transplantation (FMT) can safely reduce severe diarrhea caused by immune checkpoint inhibitors (ICIs) in cancer patients. Four adults who have persistent diarrhea despite steroids or other medications will receive a stool preparation from a healthy donor via colonoscopy. The goal is to see if the healthy bacteria can restore gut health and ease symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fecal microbiota transplantation (FMT) from a healthy donor
What this could lead to: If it works, this could offer a new way to manage severe diarrhea caused by cancer immunotherapy, helping patients stay on their cancer treatment.
What could go wrong: This is a very early, small pilot study with only 4 participants. The approach may not work for everyone, and there are risks like infection or worsening symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FECAL MICROBIOTA TRANSPLANTATION (FMT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FECAL MICROBIOTA TRANSPLANTATION (FMT)

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.